ArticleChemical science2025
Acid-responsive singlet oxygen nanodepots.
Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Platelet Membrane Biomimetic Chemiluminescent Nanoparticles for Targeted Therapy of Atherosclerosis.ACS applied materials & interfaces · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The singlet oxygen carrier addresses the challenges of traditional photodynamic therapy (PDT), which relies on the presence of oxygen within solid tumors and struggles with light penetration issues. However, the inability to control the release of singlet oxygen has hindered precise treatment applications. Here, we introduce an acid-responsive singlet oxygen nanodepot (aSOND) designed to overcome this limitation. The aSOND is synthesized using a responsive diblock copolymer system that includes a hydrophilic PEG block and a pH-responsive block with singlet oxygen loading sites. In neutral or alkaline environments, the aSOND releases singlet oxygen slowly, ensuring stability in blood circulation. In contrast, in acidic environments such as the tumor microenvironment or intracellular lysosomes, protonation of the tertiary amine group within the pH responsive block increases the hydration of the polymer, triggering a rapid release of singlet oxygen. This feature enables controlled, tumor-specific release of reactive oxygen species (ROS). The aSOND system effectively implements an "OFF-ON" singlet oxygen therapy, demonstrating high spatiotemporal selectivity and independence from both oxygen supply and external light, offering a promising approach for targeted cancer therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.